β-Blockers Linked to Reduced Mortality in HFrEF, A-Fib

Share this content:
β-Blockers Linked to Reduced Mortality in HFrEF, A-Fib
β-Blockers Linked to Reduced Mortality in HFrEF, A-Fib

THURSDAY, Jan. 12, 2017 (HealthDay News) -- β-blockers are associated with significantly reduced mortality, but not hospitalizations, in patients with heart failure and reduced ejection fraction (HFrEF) and atrial fibrillation (AF), according to a study published online Jan. 11 in JACC: Heart Failure.

Julia Cadrin-Tourigny, M.D., from the Université de Montréal, and colleagues examined the impact of β-blockers on mortality and hospitalizations in patients with AF and HFrEF in the AF-CHF trial. Among 1,376 subjects randomized in the trial, the authors propensity-matched those without β-blockers at baseline to a maximum of two exposed patients.

The researchers found that β-blockers correlated with significantly lower all-cause mortality (hazard ratio [HR], 0.721; 95 percent confidence interval [CI], 0.549 to 0.945; P = 0.0180) but not hospitalizations (HR, 0.886; 95 percent CI, 0.715 to 1.100; P = 0.2232) during a median follow-up of 37 months. In sensitivity analyses that modeled β-blockers as a time-dependent variable the results were similar (HR for all-cause mortality, 0.668; 95 percent CI, 0.511 to 0.874; P = 0.0032; HR for hospitalizations, 0.814; 95 percent CI, 0.653 to 1.014; P = 0.0658). With respect to mortality and hospitalizations, there were no significant interactions for β-blockers and pattern or burden of AF.

"These results support current evidence-based recommendations for β-blockers in patients with HFrEF, whether or not they have associated AF," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »